Australia Halts AstraZeneca Vaccine For Under 50s Over Blood Clot Concerns
In a further setback for Australia's already halting coronavirus vaccine rollout, officials said the AstraZeneca shot should no longer be given to people under the age of 50, unless they had already received a first dose without any ill effects.
Australia on Thursday joined a growing number of countries halting the use of the AstraZeneca coronavirus vaccine for younger people over fears it can cause serious blood clots.
In a further setback for Australia's already halting coronavirus vaccine rollout, officials said the AstraZeneca shot should no longer be given to people under the age of 50, unless they had already received a first dose without any ill effects.
Prime Minister Scott Morrison held an evening press conference to announce the decision shortly after the government's medical advisory board decided to follow European and other countries in limiting the use of AstraZeneca.
"It has not been our practice to jump at shadows, it has not been our practice to take unnecessary precautions," he said in explaining the step.
"We've been taking the necessary precautions based on the best possible medical advice."
Australia has been one of the world's most successful countries in containing the spread of Covid-19, with fewer than 30,000 cases and 1,000 deaths for a population of 25 million and virtually no ongoing community transmission.
But it has fallen far behind the government's own schedule for vaccinating people against the disease, with just a million doses administered by Thursday when it had pledged to give four million doses by last week.
Australia had counted on using AstraZeneca to inoculate most of its population, first using doses imported from Europe and then locally manufactured vaccines.
But vaccine shortages in Europe led to delays in AstraZeneca shipments, while planned deliveries of alternative vaccines like Pfizer/BioNTech and Novavax have not yet ramped up.
Several European countries have already suspended the use of AstraZeneca's vaccine for younger populations after it was earlier banned outright in several places over blood clot scares.
The EU's medicines regulator said Wednesday that the blood clots should be listed as a rare side effect of the shot, but that the benefits of inoculation continue to outweigh the risks.
Australian officials justified the cutoff age of 50 for giving the vaccine by saying younger people were less at risk of suffering severe complications from Covid-19.
But they stressed that older Australians should continue to trust the AstraZeneca shots.
"I want to reiterate that we are strongly encouraging those 50 and over to take up the AstraZeneca vaccine -- it is a highly effective vaccine at preventing severe Covid," said Brendan Murphy, head of the government's health department.
He added that the danger from blood clots associated with the vaccine was "extraordinarily low".
There has so far been only one case of blood clotting in a patient who received the AstraZeneca vaccine in Australia.
Morrison and Murphy said they were confident there would be enough doses of the Pfizer/BioNTech and Novavax vaccines to complete the inoculation of Australian adults.
In a further setback for Australia's already halting coronavirus vaccine rollout, officials said the AstraZeneca shot should no longer be given to people under the age of 50, unless they had already received a first dose without any ill effects.
Prime Minister Scott Morrison held an evening press conference to announce the decision shortly after the government's medical advisory board decided to follow European and other countries in limiting the use of AstraZeneca.
"It has not been our practice to jump at shadows, it has not been our practice to take unnecessary precautions," he said in explaining the step.
"We've been taking the necessary precautions based on the best possible medical advice."
Australia has been one of the world's most successful countries in containing the spread of Covid-19, with fewer than 30,000 cases and 1,000 deaths for a population of 25 million and virtually no ongoing community transmission.
But it has fallen far behind the government's own schedule for vaccinating people against the disease, with just a million doses administered by Thursday when it had pledged to give four million doses by last week.
Australia had counted on using AstraZeneca to inoculate most of its population, first using doses imported from Europe and then locally manufactured vaccines.
But vaccine shortages in Europe led to delays in AstraZeneca shipments, while planned deliveries of alternative vaccines like Pfizer/BioNTech and Novavax have not yet ramped up.
Several European countries have already suspended the use of AstraZeneca's vaccine for younger populations after it was earlier banned outright in several places over blood clot scares.
The EU's medicines regulator said Wednesday that the blood clots should be listed as a rare side effect of the shot, but that the benefits of inoculation continue to outweigh the risks.
Australian officials justified the cutoff age of 50 for giving the vaccine by saying younger people were less at risk of suffering severe complications from Covid-19.
But they stressed that older Australians should continue to trust the AstraZeneca shots.
"I want to reiterate that we are strongly encouraging those 50 and over to take up the AstraZeneca vaccine -- it is a highly effective vaccine at preventing severe Covid," said Brendan Murphy, head of the government's health department.
He added that the danger from blood clots associated with the vaccine was "extraordinarily low".
There has so far been only one case of blood clotting in a patient who received the AstraZeneca vaccine in Australia.
Morrison and Murphy said they were confident there would be enough doses of the Pfizer/BioNTech and Novavax vaccines to complete the inoculation of Australian adults.